|
|
 |
|
Viewing report
|
|
|
|
The Biotech Top 10
Centient Consulting, Inc, Oct 2005, Pages: 4
The The Biotech Investor™ has identified ten public biotechnology companies that it believes will outperform the market in 2006. This report identifies the companies 'most likely to succeed,' which run the gamut from companies with blockbuster drugs, strong earnings growth and solid pipelines, to highly speculative momentum plays full of promise but as yet unproven. In between, there are companies with drugs and drug candidates with significant potential, a beaten down stock ready to recover, and a built-in diversity plan. The one thing all of the top 10 biotechs have in common is that they are expected to do well over the next twelve months.
Reasons to Purchase
- Identify the ten public biotechs believed to hold significant promise in 2006
- Examine the scientific, market and political factors driving the potential success of these companies
- Identify potential investment opportunities in biotechnology
Target Audience
- Fund managers and individual investors seeking investments in biotech
- Analysts and journalists tracking the biotechnology market
- Others seeking to understand the driving factors and market dynamics
Customers who bought this item also bought
Investing in Biotech: Profits and Pitfalls
The Top 10 Biotechnology Companies
US Biotech Market Analysis
Booming Biotech Market in India
Animal Biotechnology - Technologies, Markets and Companies
Biotech Life Sciences: A 20/20 Vision to 2020
Biotechnology in India
Whos Buying What in Biotech? Investment and Business Trends Driving Biotechnology
Biotech M&A Strategies: Deal Assessments, Trends and Future Prospects
Indian Biotechnology Market Outlook (2006)
Competitive Positioning Strategies for Japanese Biotech Companies
Competitive Positioning Strategies for South Korean Biotech Companies
|
|
|
|
